- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03504839
Same Day Subcutaneous ICD And Send Home (DASH) (DASH)
Same Day Subcutaneous ICD And Send Home
Design: Prospective, non-randomized single center study at The Ohio State University Wexner Medical Center.
Purpose: The purpose of this study is to prospectively evaluate a specific analgesia protocol designed to allow for same day discharge following implantation of the subcutaneous implantable cardiac defibrillator (S-ICD) Enrollment: Up to 40 subjects will be enrolled. Subject Population: Consecutive patients undergoing S-ICD implantation under general anesthesia or monitored anesthesia care.
Endpoints: Rate of successful completion of the protocol; Procedural complications; Serial assessment of patient perception of pain.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a prospective, nonrandomized, descriptive, single center study designed to assess the rate of successful completion of the study protocol in consecutive patients undergoing S-ICD implantation.
Objectives To prospectively evaluate the same day discharge protocol for patients undergoing S-ICD implantation.
Primary Endpoint 1. Rate of successful completion of S-ICD implantation and discharge of the patient on the same day the device is implanted using the analgesia protocol.
Secondary Endpoints
- Procedure complication (failed implantation, infection, hematoma/bleeding, etc…) within 30 days of procedure.
- Serial assessment of patient perception of pain using the graded integer pain scale of 1-10
- Side effects related to medical therapy of protocol.
- Time from beginning of recovery (defined as when the patient enters the recovery IPR room) to the time of discharge from the recovery unit.
- 30 day readmission rate after discharge following S-ICD implant
- Number of days that oral analgesics are used post discharge.
Patients will be approached for participation in the study once they have been consented for implantation of the clinically indicated S-ICD
.
Pre-procedure analgesia will be given to each patient as follows:
Acetaminophen 975 mg PO x 1 will be administered 1-2 hours prior to the procedure. and Oxycodone 10 mg PO x 1 will be administered 1-2 hours prior to the procedure. Anesthesia will be provided by anesthesiology team as MAC or general anesthesia. Local subcutaneous anesthetic will be a 50:50 mixture of 2% lidocaine and 0.5% bupivacaine; which will result in a concentration of 1% lidocaine and 0.25% bupivacaine.
Starting at ≈2 hours post procedure, the patient will then enter the "Preparation for Discharge" phase. The modified Aldrete scoring system will be used to determine eligibility for discharge home.Patients with an Aldrete score ≥ 9 will be deemed eligible for discharge home.
Additional standard ambulatory discharge criteria per the OSUWMC postanesthesia care policy statement will be applied by the nursing team, akin to all ambulatory surgery patients at OSUWMC. If the above discharge parameters (DP) are not meet, the patient will be reassessed every 30 minutes until parameters are satisfied. Once the patient satisfies the DP, the patient will complete the Pain Perception Questionnaire and be assessed for ambulation, eating/drinking and for understanding of post discharge instructions. The electrophysiology device nursing staff will review management of the S-ICD incision, device and post discharge care instructions with the patient and with the accompanying family member(s)/friend. The patient will be given instructions regarding management of pain and will be provided the following prescription for outpatient pain control Percocet 5mg/325 mg (1 tablet every 6 hours). A 2-day supply will be given.
Also, the patient will be provided a phone number to contact during business hours as well as for after hours to address questions/concerns.
The electrophysiology nursing staff will contact the patient the following day and again at about 3 days post discharge to administer the Pain Perception Questionnaire as well as to address any patient questions. The patient will then be evaluated in the Device Clinic about 10 days post implantation. The Pain Perception questionnaire will be administered and assessment of the incision and S-ICD will be completed. The last Pain Perception questionnaire will be obtained by telephone at about 30 days post implantation.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Ohio State University Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient consented for implantation of S-ICD.
- Ambulatory/outpatient patient coming to the hospital setting solely for implantation of S-ICD
- Patient agrees to participate and is able to comply with the defined study protocol, including assistance for home care and transportation for the first ≈12-18 hours post discharge, and compliance with the required follow up.
Exclusion Criteria:
- Inability or unwillingness to provide informed consent
- Patients who, for any reason, was hospitalized or in an emergency department the day prior to the S-ICD implantation, including patients transferred for S-ICD implantation
- Patients in which the hemodynamics are dependent upon intravenous pressors infusing at the time of device implantation or mechanical support, inclusive of left ventricular assist device and intravenous devices (balloon pump, Impella device).
- Age < 18 years.
- Pregnancy.
- Currently incarcerated.
- Hypoxia (room air oxygen <91%) or acutely short of breath.
- Hypotension (Systolic blood pressure <90) unless this is patient's typical blood pressure).
- Bradycardia (heart rate <45bpm, unless this is patient's typical resting heart rate).
- Acute electrolyte disorder that cannot be easily corrected (e.g., potassium supplementations) based upon Chem 6 values obtained on day of procedure.
- Presence of a fever.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Intervention
S-ICD implantation.
|
Receiving a SICD and discharged the same day
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of Successful Completion of S-ICD Implantation and Discharge of the Patient on the Same Day the Device is Implanted Using the Analgesia Protocol.
Time Frame: within 30 days of the procedure
|
Rate of successful completion of S-ICD implantation and discharge of the patient on the same day the device is implanted using the analgesia protocol.
|
within 30 days of the procedure
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Procedure Complication (Failed Implantation, Infection, Hematoma/Bleeding, Etc…) Within 30 Days of Procedure.
Time Frame: within 30 days of the procedure
|
Procedure complication (failed implantation, infection, hematoma/bleeding, etc…) within 30 days of procedure.
|
within 30 days of the procedure
|
Serial Assessment of Patient Perception of Pain Using the Graded Integer Pain Scale of 0-10
Time Frame: within 30 days of the procedure
|
Serial assessment of patient perception of pain using the graded integer Numeric Pain Rating Scale (NPRS) of 0-10.
This is an unidimensional measure of pain intensity in adults.
Zero being no pain, 1-3 being mild pain, 4-6 being moderate pain, 7-10 being severe pain.
|
within 30 days of the procedure
|
Side Effects Related to Medical Therapy of Protocol.
Time Frame: within 30 days of the procedure
|
Side effects related to medical therapy of protocol.
|
within 30 days of the procedure
|
Time From Beginning of Recovery (Defined as When the Patient Enters the Recovery IPR Room) to the Time of Discharge From the Recovery Unit.
Time Frame: within 30 days of the procedure
|
Time from beginning of recovery (defined as when the patient enters the recovery IPR room) to the time of discharge from the recovery unit.
|
within 30 days of the procedure
|
30 Day Readmission Rate After Discharge Following S-ICD Implant
Time Frame: within 30 days of the procedure
|
30 day readmission rate after discharge following S-ICD implant
|
within 30 days of the procedure
|
Number of Days That Oral Analgesics Are Used Post Discharge.
Time Frame: within 30 days of the procedure
|
Number of days that oral analgesics are used post discharge.
|
within 30 days of the procedure
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Toshimasa Okabe, MD, Ohio State University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2017H00451
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiomyopathies
-
St. Jude Children's Research HospitalRecruitingChildhood Cancer | Cardiomyopathy, PrimaryUnited States
-
Nantes University HospitalUniversity Hospital, Angers; University Hospital, Brest; University Hospital,...Not yet recruiting
-
Yale UniversityPfizerRecruitingCardiomyopathies, PrimaryUnited States
-
Medical University of WarsawRecruitingHeart Failure | Myocarditis | Immunosuppression | Cardiomyopathies, Secondary | Endomyocardial BiopsyPoland
-
Centre Hospitalier Universitaire de NiceTerminatedDiabetic CardiomyopathiesFrance
-
Groupe Hospitalier Paris Saint JosephCompleted
-
University Hospital BirminghamBritish Heart FoundationUnknownDiabetic CardiomyopathyUnited Kingdom
-
Oliver StrohmBayerCompletedCardiomyopathy, Dilated | Cardiomyopathies, SecondaryCanada
-
Applied Therapeutics, Inc.Active, not recruitingDiabetic CardiomyopathiesUnited States, France, Spain, Australia, Canada, United Kingdom, Germany, Czechia, Hong Kong, Poland
-
University Hospital, Strasbourg, FranceUnknown
Clinical Trials on Subcutaneous ICD with same day discharge
-
Rothman Institute OrthopaedicsThe Anderson Orthopaedic ClinicCompletedOsteoarthritis of the HipUnited States
-
Barretos Cancer HospitalCompleted
-
Massachusetts General HospitalWithdrawnAtrial FibrillationUnited States
-
Indus Hospital and Health NetworkCompletedAngioplasty | CoronaryPakistan
-
Lawson Health Research InstituteActive, not recruiting
-
The Cleveland ClinicCompleted
-
Helse Stavanger HFCompletedCoronary Artery DiseaseNorway
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Heart FailureUnited States
-
Piedmont HealthcareMedtronicTerminatedAcute Coronary SyndromeUnited States
-
Yale UniversityWithdrawnReconstructive Pelvic Surgery